Collegium Pharmaceutical (COLL) Income from Continuing Operations (2014 - 2026)

Collegium Pharmaceutical's Income from Continuing Operations history runs 13 years deep, the most recent figure standing at 14496000.0 for Q1 2026.

• On a quarterly basis, Income from Continuing Operations rose 499.75% year-over-year to 14496000.0 in Q1 2026; TTM through Mar 2026 was 74949000.0, a 70.75% increase from a year earlier, with the FY2025 full-year figure at 62870000.0, down 9.13% from the prior year.
• Income from Continuing Operations eased to 14496000.0 in Q1 2026 per COLL's latest filing, from 16963000.0 in the prior quarter.
• Across five years, Income from Continuing Operations topped out at 31940000.0 in Q4 2023 and bottomed at 17426000.0 in Q1 2023.
• The 5-year median for Income from Continuing Operations is 12536000.0 (2024), against an average of 9982882.35.
• Across the five-year window, Income from Continuing Operations sank 183.44% in 2022 and soared 4415.1% in 2023, its largest moves.
• Year by year, Income from Continuing Operations stood at 7199000.0 in 2022, then soared by 543.67% to 31940000.0 in 2023, then sank by 60.75% to 12536000.0 in 2024, then surged by 35.31% to 16963000.0 in 2025, then declined by 14.54% to 14496000.0 in 2026.
• Per Business Quant, the three latest COLL Income from Continuing Operations figures stand at 14496000.0 (Q1 2026), 16963000.0 (Q4 2025), and 31507000.0 (Q3 2025).